Introduction
Clinical Implmentation Guide Objectives
COVID-19 Therapeutics under Emergency Use Authorization (EUA)
HHS’s COVID-19 Therapeutics Homepage & Announcements
Module 1: COVID-19 Outpatient Therapeutics Overview
Who Is At Risk for Severe COVID-19?
Summary of COVID-19 Preventative Agents/Treatments
NIH Guidelines For Treatment of Mild to Moderate COVID-19 in Non-hospitalized Adults Who Are at High Risk of Progressing to Severe COVID-19
NIH: Patient Prioritization for Treatment
Recommendation for Special Populations: Immunocompromised & Pediatrics
Module 2: Product Information
Paxlovid
Veklury
Lagevrio
Module 3: Oral Antiviral Administration
Patient Flow for Antiviral Oral Therapies
About Test to Treat
Test to Treat Site Locator
Module 4: Reimbursement
CMS Resources
Veklury Billing
Module 5: Additional Resources
COVID-19 Vaccination after mAb Administration
Reporting Cadence
COVID-19 Therapeutic Resourcs
Module 6: Appendices
Appendex A: Outpatient Infusion Site Resources
Appendix B: COVID-19 Convalescent Plasma
Appendix C: Formerly-Authorized Products
